Open-label Expanded Access Program on safety measures during the treatment of HIV-1 positive pregnant patients or women who want to become pregnant, with Viracept using the 625-mg tablet

Trial Profile

Open-label Expanded Access Program on safety measures during the treatment of HIV-1 positive pregnant patients or women who want to become pregnant, with Viracept using the 625-mg tablet

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Nelfinavir (Primary)
  • Indications HIV-1 infections; Pregnancy
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top